• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » iCad shakes up its board of directors

iCad shakes up its board of directors

October 3, 2018 By Brad Perriello

iCadiCad (NSDQ:ICAD) shook up its board of directors after a member tendered his resignation, naming a new chairman and re-jiggering the composition of its oversight committees.

Andy Sassine, a longtime shareholder who owns a 7.5% stake in the cancer detection company, joined the board in 2015. In his Sept. 26 resignation letter, Sassine said he grew disenchanted with the board’s seeming unwillingness to properly guide iCad.

“I can no longer stand idly by while the Board’s inaction and misdirection directly harms the interests of iCad’s shareholders,” Sassine wrote, citing the board’s failure to examine the firm’s poor stock performance, “questionable” governance practices including “a long-tenured board in dire need of a refresh” and executive compensation packages that have grown even as management missed its operational and revenue targets three years in a row.

“It has become clear to me that the board, as currently constituted, is truly incapable of acting independently of management and taking the steps required to enhance shareholder value. That I have not been appointed to a single board committee over the past three years speaks to this board’s general unwillingness to consider independent views in the boardroom,” Sassine wrote. “Debate in the board room is critical to allow for the productive analysis of the important issues facing the company. But rather than engage in an open, robust dialogue, this board has followed a path of complacency and acquiescence while largely dodging the serious issues it faces.”

Sassine said he stepped down to nominate a slate of six directors at iCad’s annual shareholders meeting. But after his resignation, he and the company hashed out a deal to revamp the board, appointing three new directors to replace three who retired, and naming a new chairman. Yesterday Sassine withdrew his resignation and was re-appointed to the group.

iCad also shuffled the makeup of its committees, naming Sassine as a member of the audit committee and chairman of the compensation committee, according to a regulatory filing.

Filed Under: Oncology, Wall Street Beat Tagged With: iCad Inc.

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy